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Abstract
Mutations leading to premature termination codons in ATP-Binding Cassette Subfamily A Member 7 (ABCA7) are high pen-
etrant risk factors of Alzheimer’s disease (AD). The influence of other genetic variants in ABCA7 and downstream functional 
mechanisms, however, is poorly understood. To address this knowledge gap, we investigated tandem repetitive regions in 
ABCA7 in a Belgian cohort of 1529 AD patients and control individuals and identified an intronic variable number tandem 
repeat (VNTR). We observed strong association between VNTR length and a genome-wide associated signal for AD in the 
ABCA7 locus. Expanded VNTR alleles were highly enriched in AD patients [odds ratio = 4.5 (1.3–24.2)], and VNTR length 
inversely correlated with amyloid β1–42 in cerebrospinal fluid and ABCA7 expression. In addition, we identified three novel 
ABCA7 alternative splicing events. One isoform in particular—which is formed through exon 19 skipping—lacks the first 
nucleotide binding domain of ABCA7 and is abundant in brain tissue. We observed a tight correlation between exon 19 
skipping and VNTR length. Our findings underline the importance of studying repetitive DNA in complex disorders and 
expand the contribution of genetic and transcript variation in ABCA7 to AD.
Keywords Alzheimer’s disease · ATP-Binding Cassette, Sub-Family A, Member 7 (ABCA7) · Variable number tandem 
repeat (VNTR) · Alternative splicing · Cerebrospinal fluid (CSF) biomarkers
Introduction
Alzheimer’s disease (AD) is a highly prevalent, incurable, 
multifactorial neurodegenerative disease with a long presymp-
tomatic phase of several decades. ATP-Binding Cassette Sub-
family A Member 7 (ABCA7) was identified as a risk factor 
for AD through genome-wide association studies (GWAS) [16, 
17, 23, 24, 31, 41]. Subsequently, rare heterozygous premature 
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termination codon (PTC) mutations in ABCA7 were identi-
fied and were up to five times more frequent in AD patients. 
Up to 4% of AD patients in Caucasian populations carry 
an ABCA7 PTC mutation [2, 10, 15, 22, 38, 40, 46, 48]. In 
African Americans (AA) a PTC-causing 44 bp exonic dele-
tion (rs142076058) was identified in 15% of patients, which 
doubled AD risk, and explained an AA-specific GWAS hit 
[9]. Risk-increasing PTC mutations are not confined to spe-
cific ABCA7 protein domains, proposing reduction of over-
all ABCA7 dosage—due to nonsense mediated mRNA decay 
(NMD) or inactive truncated proteins—as the most plausible 
pathomechanism. ABCA7 is deemed to be involved in phago-
cytosis and/or lipid metabolism and is mainly expressed in hip-
pocampal neurons and microglia in the brain [20]. Knockout 
of the mouse ortholog Abca7 was shown to reduce phagocytic 
clearance of amyloid β (Aβ) [12, 21, 39], the main constituent 
of senile plaques, which together with neurofibrillary tangles 
and reactive gliosis form the neuropathological hallmarks of 
AD.
To date, however, a biological variant explaining the GWAS 
association in Caucasian cohorts remained elusive. None of the 
PTC mutations are in linkage disequilibrium (LD) with associ-
ated GWAS SNPs. Studies have shown association between 
GWAS SNP rs3764650 and ABCA7 expression, albeit in oppo-
site directions [3, 49]. Methylation of CpG sites in the ABCA7 
promoter region was independent of this SNP [54]. Possibly, 
rs3764650 itself could directly affect AD risk [4], however 
conditional regression analyses suggest a stronger association 
with a less frequent SNP rs78117248 [10, 22]. No apparent 
biological consequences can be linked to rs78117248 (e.g. 
no overlap with transcription factor motifs), but its stronger 
association suggests the presence of a yet unknown common 
genetic variant underlying the discovery of ABCA7 as a sus-
ceptibility locus of AD.
We previously sequenced the ABCA7 locus—including 
coding, intronic, upstream and downstream sequences—in 
the Belgian AD cohort, which identified PTC mutations, but 
did not reveal a functionally strong genetic variant that could 
explain the GWAS signal [10]. Here we report the identifica-
tion of a variable number of tandem repeats (VNTR) with a 
25 bp repeat unit located in intron 18 of ABCA7, immediately 
flanking exon 18 and including the exon 18 splice donor site 
(chr19:1049437–1050028 [hg19]). We assessed the role of this 
ABCA7 VNTR in AD and associated cerebrospinal fluid (CSF) 
biomarkers, expression, and alternative splicing.
Materials and methods
Study population
Participants were part of a large prospective cohort of Bel-
gian AD patients and healthy elderly control individuals. 
Patients were ascertained at the Memory Clinic of Middel-
heim and Hoge Beuken (Hospital Network Antwerp, Bel-
gium), and at the Memory Clinic of the University Hospi-
tals of Leuven, Belgium. Possible, probable, and definite 
AD diagnosis was based on NINCDS-ADRA [28] and/or 
NIA-AA [18, 29] criteria. Control individuals were recruited 
from partners of patients, or were volunteers from the Bel-
gian community. All control individuals scored > 25 on the 
Montreal Cognitive Assessment (MoCA) test [32], and were 
negative for subjective memory complaints, neurological or 
psychiatric antecedents, and family history of neurodegen-
eration. All participants and/or their legal guardian provided 
written informed consent before inclusion. The study proto-
cols were approved by the ethics committees of the Antwerp 
University Hospital and the participating neurological cent-
ers at the different hospitals of the BELNEU consortium 
and by the University of Antwerp. Table S1 provides an 
overview of individuals for whom DNA, Epstein-Barr virus 
transformed lymphoblastoid cell lines (LCL), or CSF were 
included.
VNTR genotyping
Genomic start and end coordinates of the ABCA7 VNTR 
were delineated with the Tandem Repeat Finder algorithm 
[6], as implemented in the Tandem Repeats Database 
(TRDB) [14]. To further assess whether the VNTR length 
could contribute to AD risk, we used the genotyping meth-
ods described below.
ABCA7 VNTR identification with NGS data
We analyzed the depth of NGS sequencing reads aligning to 
the ABCA7 VNTR as a proxy for VNTR length. BAM files 
from 772 AD patients, and 757 matched healthy elderly con-
trol individuals—generated as previously described [10]—
were used for this purpose. The total number of reads in the 
BAM file and the number of reads mapping to the VNTR 
core sequence (chr19:1049514–1049953 [hg19]), which 
excludes sequencing reads aligning to the VNTR break-
points, were calculated with Rsamtools [30]. Individuals 
with very low coverage (≤ 5 VNTR sequencing reads) were 
not included. VNTR coverage was then normalized by divi-
sion by the total number of reads for that sample. Associa-
tion between normalized coverage and SNP genotypes was 
calculated with a genotypic Kruskal–Wallis test. D′ and r2 
LD values were established previously [10].
To analyze the association between VNTR size and 
GWAS SNP genotypes in an extended population, we used 
NGS data of the 1000 Genomes Project [1]. Aligned low 
coverage whole genome sequencing data from European 
individuals (i.e. British in England and Scotland, Finnish in 
Finland, Iberian populations in Spain, Utah residents with 
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Northern and Western European ancestry, and Tuscany in 
Italy) were processed in an analogous manner as the Belgian 
NGS dataset described above.
PCR and Sanger sequencing of short VNTR alleles
We designed a PCR protocol to amplify ABCA7 VNTRs up 
to approximately 3 kb. This upper limit is determined by 
PCR efficiency, which is inversely correlated with increas-
ing amplicon size and hampered by high GC content. 
We used the Kapa 2G Robust HotStart PCR Kit (Sigma-
Aldrich, Saint Louis, MO, USA), with a custom protocol as 
described in the Supplementary Methods. The forward and 
reverse primer sequences, used in this setting, were respec-
tively 5′-GGC TCA GCC TGG ACT TCT AC-3′ and 5′-TCC 
AAA ACC CTG TGA TAG CC-3′. The shortest VNTRs were 
Sanger sequenced, to determine the minimal number of tan-
dem repeats. PCR products were purified with ExoSAP-IT 
(Thermo Fisher Scientific, Waltham, MA, USA), dideoxy 
terminated with BigDye Terminator v3.1 Cycle Sequencing 
Kit (Thermo Fisher Scientific), and processed on an ABI 
3730 DNA Analyzer (Thermo Fisher Scientific), according 
to the manufacturer’s protocol. Analysis was done with Seq-
Man II software (DNASTAR, Madison, WI, USA).
Southern blotting
Southern blotting was used to genotype VNTR lengths in 
275 patients and 177 control individuals (Table S1, Fig. 
S1), including individuals without pathogenic mutations 
[8] in APP, PSEN1, and PSEN2, or ABCA7 PTC muta-
tions (incl. rs200538373) [10]. Furthermore, we excluded 
individuals for whom only a single band on Southern blot-
ting was observed, since this could reflect failed detection 
of the second VNTR allele. The Southern blotting protocol 
was adapted from the DIG Application Manual For Filter 
Hybridization (Roche, Basel, Switzerland) (details provided 
in Supplementary Methods).
Statistical analyses on Southern blotted VNTR alleles 
were performed in R3.3.2 [35], unless mentioned other-
wise. VNTR allele distribution was compared to genotypes 
of rs3764650 and rs78117248, which were determined 
previously [10, 45]. Association between SNP genotypes 
and phenotype was assessed with allelic Fisher exact tests. 
VNTR length association testing per SNP was done with a 
Kruskal–Wallis Rank Sum test. Optimal VNTR size cut-
off to distinguish expanded and wild-type VNTR lengths 
was determined as the largest VNTR allele length observed 
in control individuals without an rs3764650 risk allele. 
Association testing and calculation of odds ratio (OR) with 
95% confidence interval (95% CI) between expanded and 
wild-type allele carriers in patients and controls was calcu-
lated with Fisher exact testing. Calculations of heritability 
attributable to an ABCA7 VNTR expansion were performed 
with INDI-V [52], assuming AD heritability of liability of 
79% [13], a 13% risk of AD after age 65 years [42], and a 
multiplicative model. Association of VNTR length with age 
at onset (AAO) within patients was calculated with linear 
regression, using the sum of VNTR alleles or longest VNTR 
allele, APOE ε4 dosage, and gender as independent vari-
ables. AAO difference between patients with and without an 
expanded VNTR allele was assessed using a Mann–Whitney 
U test.
To test whether VNTR allele lengths share a haplotype 
with ABCA7 PTC mutations, we used Southern blot to geno-
type VNTR length in an additional seventeen individuals 
carrying a previously identified PTC mutation [10]. These 
individuals were not included in any statistical analyses.
Correlation between VNTR and CSF biomarkers
CSF concentrations of amyloid β1–42 (Aβ1–42), phosphoryl-
ated  tau181P (P-tau181P), and total tau (T-tau) were deter-
mined for a subset of 168 patients from the Southern blot-
ting cohort (Table S1) as part of their diagnostic work-up 
with commercially available single parameter ELISA kits 
(Fujirebio Europe, Ghent, Belgium). Linear regression with 
the sum of VNTR alleles or longest VNTR allele as the 
independent variable and  log2 transformed biomarker levels 
as the dependent variable was calculated in R [35]. Results 
are reported as β-regression coefficients with standard error 
(SE) and p value.
Expression studies
Procedures for RNA extraction, cDNA generation and char-
acteristics of the LCL cohort are given in Supplementary 
Methods.
Quantitative real time PCR
Quantitative real time PCR (qRT-PCR) was performed with 
the TaqMan Fast Advanced Master Mix (Thermo Fisher Sci-
entific), according to the manufacturer’s protocol in a 384-
well plate setting on LCL RNA. Each sample-gene pair was 
conducted in triplicate and on two different cDNA batches 
from separate RNA extractions. ABCA7 transcripts were 
targeted using the Hs01105117_m1 Taqman assay, with 
primers located in exon 45 and 46 of ABCA7 (Fig. 1), and 
three reference genes were used: HPRT1 (Hs02800695_m1), 
GAPDH (Hs99999905_m1), and YWHAZ (Hs00237047_
m1). The PCR protocol (2 min at 50 °C, then 20 s at 95 °C, 
followed by 40 cycles of 1 s at 95 °C, and 20 s at 60 °C), 
and fluorescence detection was performed on a ViiA 7 Real-
Time PCR System (Thermo Fisher Scientific). Ct values 
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were exported to Qbase+ (Biogazelle, Gent, Belgium) to 
calculate relative expression.
Identification of novel alternatively spliced isoforms
Splicing events in proximity to the VNTR were identi-
fied using cDNA PCR amplification followed by Sanger 
sequencing in both LCL and brain cDNA. Forward primers 
were positioned in exon 17 (5′-TTT CGG AGG AGC TAC TGG 
TG-3′), or on the exon18-cryptic-acceptor-splice-site-break-
point (5′-GAC CCA AAG GCC TGG AGA -3′), and paired 
with a reverse primer in exon 20 (5′-GTG CTC GTC CAC 
GGT CAG -3′). Amplification was performed with Titanium 
Taq (Clontech Laboratories, Mountain View, CA, USA) in 
a 1 M betain solution using the following thermal cycler 
protocol: 2 min at 95 °C, followed by 35 cycles of 30 s at 
95 °C and 1.5 min at 68 °C, and finished by 3 min at 68 °C. 
The Sanger sequencing reaction was then carried out with 
BigDye Terminator v3.1 Cycle Sequencing Kit (Thermo 
Fisher Scientific), and subsequently processed on an ABI 
3730 DNA Analyzer (Thermo Fisher Scientific). Analysis 
was performed with Seqman software (DNASTAR, Madi-
son, WI, USA). All splicing events were further confirmed 
by analyzing in-house RNAseq data (described in Verheijen 
et al. [50]) with the use of Integrative Genomics Viewer 
(IGV) software [37].
Isoform quantification
Capillary fragment analysis was used to quantify eight 
observed isoform combinations. PCR amplification of 
cDNA was analogous to the isoform identification method 
described above, using a 5′ FAM-labeled forward primer 
in exon 17 (5′-TTT CGG AGG AGC TAC TGG TG-3′), and an 
Fig. 1  Genomic location of the ABCA7 VNTR and its effect 
on ABCA7 splicing. a The ABCA7 genomic conformation 
(NM_019112.3) and positions of rs3764650, the VNTR, and 
rs78117248 are shown. Pairwise D′ and r2 between rs3764650 and 
rs78117248 is noted on top. Black arrows superimposed on exons 
45 and 46 indicate the primers used for qPCR. Below, ABCA7 exons 
17–20 (blue rectangles), introns (black line), VNTR units (black rec-
tangles), and primers in exons 17 and 20 for isoform quantification 
(black arrows) are represented. Twelve VNTR units are depicted, cor-
responding to the smallest observed VNTR length. The 25 bp VNTR 
unit sequence is shown in more detail, with the first two bases cor-
responding to a splice donor site. Caret-like exon connecting lines 
depict canonical (green), exon 18 cryptic splice acceptor (orange), 
retention of a single VNTR unit (purple) and exon 19 skipping (red) 
splicing. b Canonical spicing of the entire ABCA7 gene leads to a full 
length ABCA7 protein, containing two nucleotide binding domains 
(NBD). Usage of a cryptic splice acceptor in exon 18 and retention 
of a single VNTR unit lead to a frameshift, which causes a prema-
ture termination codon (PTC) that leads to either a truncated protein 
or degradation of the mRNA via nonsense mediated mRNA decay 
(NMD). Complete skipping of exon 19 causes a deletion of 44 amino 
acids embedded in the first ABCA7 NBD
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exon 20 reverse primer (5′-GTG CTC GTC CAC GGT CAG 
-3′). The PCR amplicons were then supplemented with 
formamide and GeneScan 600 LIZ Size Standard (Thermo 
Fisher Scientific) and size separated on an ABI 3730 DNA 
Analyzer (Thermo Fisher Scientific). Analysis was per-
formed with MAQ-S v1.5.0 software (Agilent). Manual 
inspection was performed to confirm that fluorescence sig-
nals corresponded to the expected size, and signal heights 
were within quantifiable range. Ratios for canonical, exon 18 
cryptic splice acceptor, and exon 19 skipping isoforms were 
calculated as the signal area of the corresponding isoform 
peaks divided by the total area of these peaks.
Allele‑specific isoform expression
To examine the effect of individual VNTR alleles on ABCA7 
isoform abundancy we performed allele-specific isoform 
expression on an individual with a small (837 bp) and large 
(9711 bp) VNTR allele, and heterozygosis (A/G) for nearby 
exonic polymorphism rs3752240. VNTR alleles were phased 
with rs3752240 on genomic DNA according to the “short 
VNTR allele PCR protocol” (Supplementary Methods) 
using primers 5′-CAA GAC CAC CAC CCT GTG A-3′ and 
5′-AGA GAT GGG GAA GGG ACC TC-3′. Since the largest 
allele is too large for PCR amplification, only the shortest 
allele will be observed, allowing phasing. RNA extraction 
and cDNA synthesis was performed as described above. 
Subsequently the “Isoform quantification PCR protocol” 
was used for which the forward and reverse primers were 5′ 
supplemented with Illumina Nextera Adapters (5′-TCG TCG 
GCA GCG TCA GAT GTG TAT AAG AGA CAG-3′ and 5′-GTC 
TCG TGG GCT CGG AGA TGT GTA TAA GAG ACAG-3′ 
respectively). The amplicon was then PCR barcoded with i5 
and i7 adapters and 300 bp paired end sequenced on MiSeq 
with v3 chemistry (Illumina, San Diego, CA, USA). GMAP 
was used to align and output splicing events of sequencing 
reads [53]. Genotypes for rs3752240 per read were deter-
mined with samtools [25].
Statistical analysis of ABCA7 overall and isoform 
quantifications
The qRT-PCR and isoform quantifications were compared to 
the sum of the VNTR alleles. Since the difference between 
two VNTR alleles within an LCL sample was kept to a 
minimum (Supplementary Methods), the VNTR sum value 
corresponds well to the underlying individual alleles. Asso-
ciation between expression and VNTR sum was calculated 
with linear mixed-effects models, using lme4 in R [5, 35], 
correcting for gender and batch in which LCL were grown. 
The full model was compared to the null model (without 
VNTR sum) using a Likelihood Ratio test. Linear regression 
was used to calculate the expression fold change between 
different VNTR sizes. The analyses were additionally 
performed using the longest VNTR allele as independent 
variable.
Results
VNTR identification and correlation with the GWAS 
index SNP at ABCA7
We examined repetitive regions in ABCA7, which were 
poorly assessed by conventional NGS data analysis, in our 
previously generated NGS dataset [10]. This revealed many 
sequencing reads with low mapping quality in intron 18, 
close to exon 18, aligning to a low complexity C-rich region. 
Further inspection indicated a 25 bp tandem repeating pat-
tern. The VNTR comprises 592 bp of the human reference 
genome (chr19:1049437–1050028 [hg19]), corresponding 
to 23.7 repetitions of the 25 bp VNTR core repeat motif 
(Fig. 1). The first two nucleotides (GT) of the VNTR cor-
respond to the canonical splice donor site of exon 18. The 
sequence between VNTR repeat units can vary slightly (Fig. 
S2).
First, we investigated the depth of NGS sequencing reads 
aligning to the VNTR (chr19:1049514–1049953 [hg19]) as 
a proxy for VNTR length, in relation to the genotype of 
ABCA7 GWAS index SNP rs3764650. Carriers of the risk 
increasing rs3764650[G]-allele had increased read depth in 
the Belgian cohort (n = 1529; Fig. S3, p = 2.2 × 10−16) [10], 
as well as in low coverage whole genome sequencing data in 
European subjects derived from the 1000 Genomes Project 
(n = 403; Fig. S4, p = 0.01) [1].
To directly genotype VNTR length, we performed South-
ern blotting on 452 individuals. For each individual, two 
size-separated bands were imaged corresponding to the 
VNTR alleles; no signs of mosaicism were present (Fig. S1). 
We observed high variability in VNTR lengths between indi-
viduals. The smallest allele was 298 bp (approx. 12 repeat 
units), which could be confirmed with Sanger sequencing. 
The largest observed allele size was 10678 bp (approx. 
427 tandem repeats). Relative to the ABCA7 VNTR in the 
human reference genome (chr19:1049437–1050028 [hg19], 
592 bp), the longest VNTR length causes an eightfold size 
increase of intron 18 and a 39% extension of ABCA7 pre-
mRNA. Increasing VNTR lengths were associated with 
risk alleles of rs3764650 (p = 6.7 × 10−8) and rs78117248 
(p = 6.3 × 10−4) (Fig. 2a and Fig. S5), confirming our obser-
vations based on NGS-based approximation.
We assessed normal variability of VNTR lengths 
(median = 2388 bp, interquartile range = 2130 bp) within 
healthy elderly without an rs3764650 risk allele (n = 133) 
and observed a maximum VNTR length of 5720 bp (Fig. 
S6).
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ABCA7 VNTR expansion is associated with AD
For individuals with two alleles within the normal range 
(< 5720 bp, “wild-type”), distribution was similar between 
patients and controls (Fig. 2b). However, individuals carry-
ing an allele > 5720 bp (“expanded”), were mostly patients 
[OR 4.5 (95% CI 1.3–24.2), p = 0.008, Fig. 2b]. Twenty 
patients (7.3%) carried an expanded VNTR allele in con-
trast to three controls (1.7%) (Table S2). In this cohort, the 
heritability of liability attributable to ABCA7 VNTR expan-
sion is estimated at 3.1%. Among carriers of an expanded 
allele, the second (smaller) allele was longer in patients 
(2751 ± 1164 bp) than controls (1001 ± 652 bp). In the group 
with Southern blot data, 25% of patients and 22% of controls 
carried at least one rs3764650 risk allele. The latter is not 
significantly associated with AD in this cohort (p = 0.6), pre-
cluding conditional regression analysis. For expanded VNTR 
allele carriers, however, the proportion of rs3764650 risk 
alleles increased to 63 and 100% for patients and controls, 
respectively (Table S2). We observed no shared haplotype 
between expanded VNTR alleles and ABCA7 PTC muta-
tions (Fig. S7). Patients with an expanded VNTR allele had 
an onset age ranging from 44 to 90 years. The age at inclu-
sion for all three control individuals falls within this range 
(Table S2). We observed no association between VNTR 
length and onset age in patients (p = 1, Table S3, Table S4), 
nor for expanded VNTR allele carriers compared to other 
patients (p = 0.9). We analyzed the correlation of VNTR 
length with CSF biomarkers for AD (Fig. 3a–c) in 168 AD 
patients. A decrease in Aβ1–42 was observed with increas-
ing VNTR length (βlog(Aβ) = − 4.6 × 10−5, SE = 2.1 × 10−5, 
p = 0.03 for sum of VNTR alleles). For P-tau181P, a directly 
proportional trend was observed, albeit not significant 
(βlog(p-tau) = − 4.0 × 10−5, SE = 2.3 × 10−5, p = 0.09 for sum 
of VNTR alleles). We did not detect an association of VNTR 
length on T-tau (Table S3).
VNTR length is associated with decreased ABCA7 
expression
We observed a decrease in overall ABCA7 expression with 
increasing VNTR length (β = − 4.7 × 10−5, SE = 1.9 × 10−5, 
p = 0.01 for sum of VNTR alleles) (Fig. 4a, Table S3). This 
trend was observed for both patients and controls. The aver-
age expression for the sample with the largest diploid com-
bination of VNTR alleles (5399 + 4575 bp) was 33% lower 
than the expression at the smallest diploid VNTR combina-
tion (557 + 315 bp).
ABCA7 alternative splicing is affected by VNTR 
length
We observed three separate isoform changes in exon 18 and 
exon 19 (exons flanking the VNTR), currently unknown to 
public databases (Fig. 1). These alternative splicing events 
include usage of a cryptic splice acceptor site in exon 18 
(chr19:1049314–1049316 [hg19]), usage of a cryptic 
splice donor site in intron 18 (chr19:1049461–1049463 
Fig. 2  Association of ABCA7 VNTR lengths with AD and AD-asso-
ciated SNPs. a The distribution of largest and smallest Southern blot-
ted VNTR alleles is shown in relation to the genotype of rs3764650 
and rs78117248 in three categories: homozygous reference allele 
(blue), heterozygous (green), and homozygous risk allele (red) car-
riers. These distributions are shown per phenotype in Fig. S5. b The 
main panel depicts patients (red) and healthy elderly control indi-
viduals (blue) according to their largest (x-axis) and smallest (y-axis) 
VNTR allele, as determined by Southern blotting. The upper and 
right panel show the Q–Q distance, respectively corresponding to the 
largest and smallest VNTR allele. A positive distance reflects enrich-
ment in AD patients, while a negative distance corresponds to enrich-
ment in controls
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[hg19]), and exon 19 skipping. The first two alternative 
splicing events respectively cause a 52 bp loss of coding 
sequence, and a 25 bp intron retention (corresponding to 
one VNTR repeat unit), hence both resulting in an out-of-
frame transcript. The third splicing event leads to complete 
skipping of exon 19, which causes in-frame loss of cod-
ing sequence, corresponding to 44 amino acids that are part 
of the first nucleotide binding domain (NBD) of ABCA7 
(Fig. 1). We analyzed the effect of VNTR length on abun-
dance of these splicing events in LCL (Fig. 4b). Exon 18 
alternative splicing and intron 18 retention events were not 
affected by different VNTR sizes (Table S3). Exon 19 skip-
ping, however, strongly increased with expanding VNTR 
size (p = 3.24 × 10−13 for sum of VNTR alleles; Table S3). 
This trend was present in patients and controls (Fig. 4c). 
Exon 19 skipping was 3.2 times more abundant in the LCL 
sample with the largest diploid combination of VNTR alleles 
(5399 + 4575 bp) compared to smallest VNTR combination 
(557 + 315 bp). To determine the effect of individual alleles 
on exon 19 skipping, we examined allele-specific expression 
in LCL of an AD patient with an expanded VNTR allele 
(9711 bp) and a small wild-type allele (837 bp) (Table S2)—
which were respectively phased with the rs3752240[G] and 
rs3752240[A] allele—and observed a 4.1-fold increase in 
exon 19 skipping for the expanded allele (Fig. S8).
In addition to quantification in LCL (Fig. 4d), we quanti-
fied the three alternative splicing events in the hippocampus, 
originating from six AD patients and six controls, as well as 
in Brodmann area 10 (BA10) brain tissue from four patients 
and six controls (Fig. 4e, f). For each brain tissue, three 
individuals had VNTR Southern blotted lengths and none 
carried an expanded VNTR allele. Splicing isoforms causing 
a frameshift had approximately similar expression level in all 
tissues: 14 ± 6 and 2 ± 1%, respectively. Exon 19 skipping, 
however, varied strongly between different brain regions and 
between brain and LCL: 45 ± 10% in BA10, 29 ± 12% in hip-
pocampus, and 12 ± 6% in LCL. In 90% of BA10 cases and 
31% of hippocampal tissue, the cumulative abundance of 
the alternative splicing transcripts exceeded the abundance 
of the canonically spliced transcript (Fig. 4e, f).
Since exon 18 alternative splicing and intron 18 reten-
tion introduce PTCs, they are subject to NMD. To evaluate 
whether the VNTR has an effect on NMD efficiency, we 
analyzed LCL treated with cycloheximide (CHX). Addi-
tion of CHX substantially increased the abundance of PTC 
introducing transcripts (Fig. S9), but no linear relationship 
was observed between the VNTR sum and the change in 
transcript abundance (p = 0.7 for exon 18 alternative splic-
ing) (Fig. S10).
Discussion
We report a VNTR in ABCA7 that increases risk of AD up to 
4.5-fold. VNTR length was tightly correlated with a GWAS 
index SNP for AD in ABCA7, with expansions predomi-
nantly occurring on the risk allele haplotype. VNTR length 
was negatively correlated with ABCA7 expression, in line 
with the mode of action of rare PTC mutations in ABCA7 
that increase risk of AD [2, 9, 10, 15, 22, 38, 40, 46, 48]. 
Fig. 3  Effect of the ABCA7 VNTR on CSF biomarkers of AD. Loga-
rithmic levels (y-axis) of CSF Aβ1–42 (a), P-tau181P (b), and T-tau 
(c) in AD patients corresponding to the sum of VNTR allele lengths 
(x-axis) within those patients. A trendline (blue) is shown with stand-
ard error (shaded area)
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Interestingly, VNTR expansion resulted in an increase in 
exon 19 skipping, a splicing event that has not previously 
been reported. This splicing event was most prominent in 
brain tissue.
A genetic variant with downstream biological conse-
quences underlying the GWAS association in ABCA7 in 
Caucasian AD cohorts had not been identified yet. Here, we 
show that individuals with the risk haplotype of rs3764650 
and rs78117248 have longer VNTR lengths on average. 
Furthermore, the majority of carriers with an expanded 
VNTR allele have at least one rs3764650 risk allele. Within 
this study population, rs3764650 is not associated with 
AD due to a comparable risk allele frequency in patients 
(MAF = 13.4%) and controls (MAF = 12.1%), therefore 
restricting the use of conditional regression. Neverthe-
less, the number of patients with an expanded VNTR allele 
(7.3%) is much higher than controls (1.7%), rendering this 
ABCA7 VNTR a common high-penetrant [OR 4.5 (95% CI 
1.3–24.2)] risk factor for AD. Expanded VNTR alleles were 
not in LD with ABCA7 PTC mutations, and independently 
contribute to AD risk. Within this discovery cohort, the her-
itability of liability attributable to expanded ABCA7 VNTRs 
equals 3.1%. Compared to other genetic AD risk factors, this 
estimate is second to only APOE ε4 [11].
Increasing VNTR length was associated with an over-
all reduction of ABCA7 expression. This points towards a 
similar pathomechanism as observed in ABCA7 PTC muta-
tion carriers. We observed no effect of VNTR length on 
NMD, hence ABCA7 expression reduction is not caused by 
differential proportions of alternatively spliced exon 18 and 
VNTR retention transcripts. The sequence of the ABCA7 
VNTR contains recurring transcription factor binding motifs 
for ZNF263, PLAG1, and RREB1 [27]. ZNF263 has the 
strongest expression in brain (GTEx Consortium, accessed 
November 2017) and contains a Krüppel associated box 
(KRAB) domain which is involved in transcriptional repres-
sion [26]. Hence, increased binding of ZNF263 to longer 
VNTRs could decrease ABCA7 expression. Other factors 
contributing to the effect of the VNTR on ABCA7 expres-
sion could be chromatin state in the VNTR region, and sta-
bility of pre-mRNA with varying VNTR lengths, warranting 
further investigation.
VNTR expansion resulted in increased skipping of exon 
19, which contains 132 highly conserved nucleotides (55% 
GERP-score > 2) and encodes 44 amino acids that are part of 
the first nucleotide binding domain of ABCA7. This domain 
is required for ATP hydrolysis and export of phospholipids 
[34]. Skipping of this exon can therefore cause reduction of 
functional ABCA7. Due to high abundance of this isoform 
in hippocampus and frontal cortex, it has a strong impact 
on ABCA7 dosage in brain tissue. Analysis of the VNTR 
repeat unit sequence with SpliceAid [33] revealed binding 
motifs for three splice factors in particular: SRp30c, YB-1, 
and Nova-1. SRp30c—in conjunction with YB-1 [36]—
represses the use of a downstream splice acceptor site [44], 
and was shown to regulate exon skipping in MAPT, which 
is associated with frontotemporal dementia [51]. Increase 
of SRp30c binding motifs due to ABCA7 VNTR length 
could therefore influence skipping of downstream exon 19. 
Fig. 4  Quantification of ABCA7 VNTR effects on ABCA7 expres-
sion and splicing. a–c Quantification of ABCA7 expression in LCL 
according to the sum of the two VNTR alleles within an individual 
(x-axis). a Relative RT-PCR determined ABCA7 expression targeting 
all known isoforms of ABCA7 for patients (dots) and controls (trian-
gles). A trendline (blue) is shown with standard error (shaded area). b 
The ratio of canonical (green), alternative exon 18 splicing (orange), 
VNTR unit retention (purple), and exon 19 skipping (red) shown for 
individuals (dots) and with a trendline per isoform. c Exon 19 skip-
ping shown in more detail for patients (dots), and controls (triangles) 
with a trendline and standard error (shaded area). d–f Distribution of 
the four isoforms (x-axis) across three different tissues: LCL (d), hip-
pocampus (e), and Brodmann area (BA) 10 (f)
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Nova-1 is only expressed in neurons where it affects alterna-
tive splicing [19] and could potentially explain higher exon 
19 skipping levels in brain tissue.
AD patients carrying an ABCA7 PTC mutation display 
a wide variability in onset age (45–90 years) [7, 10, 15, 
38], which may in part be explained by reduced penetrance 
due to variation in NMD efficiency and alternative splicing 
events [38]. In line with this, AD carriers of an expanded 
VNTR allele had onset ages ranging from 44 to 90 years. 
We observed no association between onset age and VNTR 
length. Of note, the age at inclusion for the three control 
individuals with an expanded VNTR allele varied from 63 
to 79 years, which is still within the onset age range. There-
fore, the current disease penetrance estimate of this ABCA7 
VNTR could be underestimated; clinical follow-up of these 
individuals is warranted. We observed nominal significant 
association between increasing ABCA7 VNTR length and 
decrease of CSF Aβ1–42, which is one of the hallmarks of 
AD [29]. This observation is in line with a previous report 
showing association between the risk allele of rs3764650 
and increased neuritic plaque load [43], and exacerbation of 
plaque load in Abca7 knockout mice [12, 21, 39].
Due to technical limitations related to long GC-rich 
tandem repeats, Southern blotting is currently the only 
method for size determination of the two VNTR alleles 
within an individual. Southern blotting is a low-throughput 
method, however, and requires highly concentrated and high 
molecular weight DNA, which limited the sample size for 
whom bi-allelic data were available. Nevertheless, due to 
the strong effect of VNTR expansion on AD risk, we were 
able to detect association between expanded VNTR alleles 
and AD in this study cohort. Furthermore, approximation 
of VNTR length based on NGS data of our full cohort as 
well as the 1000 Genomes Project supported the associa-
tion between VNTR and AD risk. Techniques are emerging 
for target enrichment of GC-rich regions [47], which may 
in the near future enable a more in-depth characterization 
of this VNTR at higher throughput. Outstanding questions 
that should then be explored include studying the effect of 
intermediate and smaller VNTR lengths on AD and its endo-
phenotypes, epistasis between the two alleles within an indi-
vidual, sequence differences between VNTR repeat units, 
nucleotide modifications, and phenotypic heterogeneity due 
to varying VNTR length.
In conclusion, we identified high penetrant expanded 
ABCA7 VNTR alleles in more than 7% of AD patients which 
increase abundance of a novel NBD-null ABCA7 isoform. 
With this study, we emphasize the need for the analysis of 
tandem repeats and their biological consequences to resolve 
indirect GWAS signals. Expanded VNTR alleles as well 
as PTC mutations in ABCA7 have a strong contribution 
to AD and both converge to a disease mechanism involv-
ing decreased ABCA7 expression. Future research will be 
paramount to study this AD subtype with potential benefit 
from ABCA7-specific therapies for AD.
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